Report ID: SQMIG35A2611
Intravenous Immunoglobulin Market Size, Share, Growth Analysis, By Application(Hypogammaglobulinemia, CIDP, Immunodeficiency Diseases, Congenital AIDS), By Type(IgG, IgM, IgA, IgE), By Distribution Channel(Hospital Pharmacy, Specialty Pharmacy, and Others), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35A2611 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
100 |
Figures:
69
Intravenous Immunoglobulin Market Dynamics
Drivers
Increasing Adoption of Intravenous Immunoglobulins to Drive Market Growth
- The pervasive uptake of intravenous immunoglobulin therapy as the foremost treatment avenue for numerous rare immunological and neurological conditions, notably primary immunodeficiency (PI) and associated diseases, emerges as a cornerstone propelling the expansion of the intravenous immunoglobulin market. This extensive acceptance of IVIG therapy as the frontline treatment signifies its efficacy and relevance in managing these conditions effectively.
Restraints
High Cost of Treatment to Impede Market Growth
- The diagnosis and treatment expenses associated with demyelinating diseases present a considerable financial burden. The rising costs linked to IVIG therapy stand out as a significant barrier to the market's expansion. Typically administered every 3 to 4 weeks, IVIG infusions are recurrent, involving approximately 12 to 16 sessions annually. The projected cost of IVIG is estimated at USD 73.89 per gram, amounting to a total expense of around USD 10,000.
Intravenous Immunoglobulin Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
